CTLT stock is trending higher after the company announced the opening of a new facility in San Diego.
Catalent Further Expands Clinical Supply Network with New Facility in San Diego
On October 28, 2021, Catalent, a global leader in clinical supply services, announced the opening a new facility in San Diego, in response to increased demand from pharmaceutical and biopharmaceutical customers for integrated development, clinical packaging, and distribution solutions on the U.S. West Coast. The new facility marks the latest expansion to Catalent’s global clinical supply network, and follows the opening of a new site in Japan earlier this month.
The 24,000-square-foot facility, located within a mile of the company’s early-phase oral drug product center of excellence, has been established to support clinical studies in phases 1-3. The site offers end-to-end services including supply management, primary and secondary packaging and labeling, storage, distribution, returns and destruction.
“Our new full-service San Diego supply facility is strategically located to work in tandem with our development center and serve customers not only on the West Coast of the U.S. and Canada, but across the world,” commented Kristen DeVito, Vice President of Operations, Clinical Supply Services, North America at Catalent. “In addition to investments we have made across our global network, the site is part of a wider strategy to provide local, integrated supply services, which offer a supply chain advantage as the world adjusts to the impact of the pandemic and its inherent logistical challenges.”
Catalent’s Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus in Harmans, Maryland, Increases to $360M
On October 26, 2021, Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announced a $230 million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland, to meet growing customer demand.
The Harmans campus, located close to Baltimore Washington International Airport (BWI), includes a now fully operational, state-of-the-art U.S. FDA- and EMA-approved facility comprising 10 commercial-scale manufacturing suites. A second facility is under construction following an initial $130 million investment by Catalent in 2020, which will add five new manufacturing suites that are expected to be operational mid-2022. This latest investment will include the construction of three additional multi-room commercial suites, as well as expanding the site’s storage capabilities for just-in-time inventory space, ultra-low temperature freezers, and its water-for-injection infrastructure. When complete at the end of 2022, the campus will house a total of 18 CGMP viral vector manufacturing suites, each designed to accommodate multiple bioreactors up to 2,000-liter scale and enable the execution of commercial manufacturing from cell bank to purified drug substance.
Other facilities, including multistory parking and an onsite cafeteria, are planned for the campus to support the significant anticipated growth in employee numbers. The expansion will see the creation of more than 700 new technical, scientific, and operational employment positions over the next six years.
“Catalent is committed to continuous improvement and growing with our customers’ futures in mind. This necessitates that we consistently incorporate our own learnings and the latest developments in CGMP manufacturing into our new and existing facilities and operations, to help assure quality and de-risk processes,” commented Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy. “By applying the expertise we have gained from the last three years of operating our flagship gene therapy commercial facility, we are able to continue to expand our campus with a design layout that is innovative, efficient, and provides ultimate flexibility for our customers.”
The Harmans/BWI campus has a total footprint of approximately 350,000 square feet and is part of Catalent’s Maryland-based network of gene therapy, plasmid DNA and oncolytic virus facilities that offer horizontally integrated solutions to support advanced therapy programs from gene to clinic. The recent addition of process development and CGMP production of plasmid DNA at multiple scales at its Rockville facility, together with its process development and CGMP cleanroom suites for early-phase viral vector programs at Baltimore BioPark, located at the University of Maryland, provide the foundation for Catalent’s commercial gene therapy manufacturing services.
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, oncolytic viruses, and live virus vaccines. An experienced and innovative partner, Catalent Cell & Gene Therapy has a global network of dedicated, small- and large-scale clinical and commercial manufacturing facilities, including an FDA-licensed viral vector facility, and fill/finish capabilities located in both the U.S. and Europe.
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.
With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually.
Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenueThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... in its 2021 fiscal year. For more information, visit http://www.catalent.com
Catalent Opens New Full-Service Clinical Supply Facility in Shiga, Japan
On October 5, 2021, Catalent, a global leader in clinical supply services, announced the opening of its new clinical supply facility, strategically located in the Shiga prefecture of Japan, in response to increased demand for end-to-end services, including primary packaging and white glove services.
The 6,000 square-meter site will provide flexible clinical supply solutions, serving both local and global biotech and pharmaceutical companies. The facility, one of the largest of its kind in Japan, will play an important role in Catalent’s expanding Asia-Pacific network, working alongside two sites in China and one in Singapore to ensure customers’ clinical trials are well-served across the region.
“Shiga will become a key hub in our Asia-Pacific Clinical Supply Services network, with Japan now representing the third-largest clinical trials market in the world,” commented Roel de Nobel, Vice President and General Manager of Asia Pacific, Catalent Clinical Supply Services. He added, “The new site builds upon Catalent’s 40 years of in-country presence, and in addition to bi-lingual English and Japanese project and clinical supply management, will provide primary and secondary packaging and labeling, storage and distribution, cold chain handling, and in-country returns and destruction services.”
Acquired from Teva-Takeda Pharmaceuticals in July 2020, the Shiga site has since undergone significant redevelopment to optimize Catalent’s service offering, and it will also add specialized solutions for the Asia-Pacific markets including Catalent’s FastChain® demand-led supply, white glove handling and logistics.
With sites in the U.S., U.K., Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services can handle a broad range of international compliance and distribution requirements to support global clinical trials.
CTLT Stock Technical Analysis
The long and short term trends are both positive. This is looking good! We also have a Pocket Pivot (blue dot) signal. CTLT is one of the better performing stocks in the Pharmaceuticals industry, it outperforms 85% of 243 stocks in the same industry.
Although CTLT has an excellent technical rating, it does not offer a high quality setup at the moment. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when CTLT stock is a good entry.